These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32624339)

  • 1. Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations.
    Pea F
    J Infect Chemother; 2020 Sep; 26(9):900-907. PubMed ID: 32624339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations.
    Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG
    Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use and therapeutic drug monitoring of teicoplanin in the UK.
    Darley ES; MacGowan AP
    Clin Microbiol Infect; 2004 Jan; 10(1):62-9. PubMed ID: 14706088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
    Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
    Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: A Systematic Review.
    Choi JS; Yoon SH; Park HJ; Lee SY; Kim YJ
    J Korean Med Sci; 2023 Feb; 38(7):e62. PubMed ID: 36808548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teicoplanin Therapeutic Drug Monitoring and Treatment Outcomes in Children With Gram-Positive Infections.
    Loane G; Gwee A
    J Pediatric Infect Dis Soc; 2021 May; 10(5):682-685. PubMed ID: 33543753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
    J Antimicrob Chemother; 2022 Mar; 77(4):869-879. PubMed ID: 35022752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin.
    Pea F; Viale P; Pavan F; Tavio M; Poz D; Beltrame A; Furlanut M
    Int J Antimicrob Agents; 2006 Apr; 27(4):344-50. PubMed ID: 16554146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interlaboratory analysis of teicoplanin plasma concentration assays among Chinese laboratories.
    Wang XX; Jin PF; Li PM; Xu S; Kong XD; Qin W; Chen WQ; Qin WJ; Zhang XL
    J Clin Pharm Ther; 2020 Oct; 45(5):983-990. PubMed ID: 31985852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
    Niwa T; Tokuma Y; Ito T; Kimura J; Tabata K; Takagi A
    Jpn J Antibiot; 2004 Aug; 57(4):413-9. PubMed ID: 15535042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
    Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
    Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance.
    Hu S; Wang T; You H; Chen S; Zhang T; Dong Y
    J Clin Pharm Ther; 2022 Oct; 47(10):1548-1555. PubMed ID: 35633105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Treatment of Teicoplanin for Methicillin-resistant Staphylococcus aureus Sternal Osteomyelitis with Renal Impairment: A Case of High Teicoplanin Trough Levels Maintained by Therapeutic Drug Monitoring.
    Shiohira H; Nakamatsu M; Kise Y; Higa F; Tateyama M; Hokama N; Kuniyoshi Y; Ueda S; Nakamura K; Fujita J
    Yakugaku Zasshi; 2016; 136(9):1313-7. PubMed ID: 27592834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.